Physician profile
Robert Goodman
NPI 1619966488
$1,640.26
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $782 · 2021: $335 · 2022: $24.39 · 2023: $74.27 · 2024: $97.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $435.62 | 2019-2022 | |
| Amgen INC. | $425.52 | 2019-2020 | |
| Abbott Laboratories | $171.32 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $130.55 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $126.18 | 2020-2021 | |
| Pfizer INC. | $60.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.22 | 2019 | |
| Edwards Lifesciences Corporation | $51.96 | 2020 | |
| Glaxosmithkline, LLC. | $39.36 | 2019-2020 | |
| Radius Health, INC. | $33.38 | 2020 | |
| Amarin Pharma, INC. | $25.45 | 2020 | |
| Arbor Pharmaceuticals, INC. | $19.25 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.09 | 2021 | |
| Hikma Pharmaceuticals USA | $18.09 | 2021 | |
| Circassia INC. | $15.14 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.